お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:悪性線維性組織球腫:世界の治験動向
市場調査レポート
商品コード
299723

悪性線維性組織球腫:世界の治験動向

Malignant Fibrous Histiocytoma Global Clinical Trials Review, H2, 2017

出版日: | 発行: GlobalData | ページ情報: 英文 73 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円
悪性線維性組織球腫:世界の治験動向
出版日: 2017年12月28日
発行: GlobalData
ページ情報: 英文 73 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、悪性線維性組織球腫に関する臨床研究の最新動向について分析し、疾患の概要を初め、G7諸国・E7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 主要国における治験件数; 中東/アフリカ地域

G7諸国における治験件数:悪性線維性組織球腫治験件数の腫瘍治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:悪性線維性組織球腫治験件数の腫瘍治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - 悪性線維性組織球腫治療薬

有望な薬剤

治験プロファイルの基本情報

付録

図表

目次
Product Code: GDHC4753CTIDB

GlobalData's clinical trial report, "Malignant Fibrous Histiocytoma Global Clinical Trials Review, H2, 2017" provides an overview of Malignant Fibrous Histiocytoma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Fibrous Histiocytoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 3
  • Report Guidance 4
  • GlobalData Clinical Trials Report Coverage 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Clinical Trials by G7 Countries: Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials 13
  • Clinical Trials by Phase in G7 Countries 14
  • Clinical Trials in G7 Countries by Trial Status 15
  • Clinical Trials by E7 Countries: Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials 16
  • Clinical Trials by Phase in E7 Countries 17
  • Clinical Trials in E7 Countries by Trial Status 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Malignant Fibrous Histiocytoma Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28

Appendix 70

  • Abbreviations 70
  • Definitions 70
  • Research Methodology 71
  • Secondary Research 71
  • About GlobalData 72
  • Contact Us 72
  • Disclaimer 72
  • Source 73

List of Tables

List of Tables

  • Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Region, 2017* 6
  • Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
  • Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 9
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
  • Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials, G7 Countries (%), 2017* 13
  • Malignant Fibrous Histiocytoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
  • Malignant Fibrous Histiocytoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
  • Proportion of Malignant Fibrous Histiocytoma to Oncology Clinical Trials, E7 Countries (%), 2017* 16
  • Malignant Fibrous Histiocytoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 17
  • Malignant Fibrous Histiocytoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Malignant Fibrous Histiocytoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Malignant Fibrous Histiocytoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Malignant Fibrous Histiocytoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.